Primary sclerosing cholangitis | Norway| PDF | PPT| Case Reports | Symptoms | Treatment

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Primary Sclerosing Cholangitis

  • Primary sclerosing cholangitis

     Disease pathophysiology: 

    Primary sclerosing cholangitis (PSC) causes inflammation and scarring of the bile ducts located inside and outside the liver. The ducts carry bile — the liquid that helps break down fat in food — out of the liver. As scarring accumulates, the ducts become blocked causing bile to build up in the liver, which damages liver cells. Eventually, if left untreated, PSC can cause liver failure or hardening of the liver, called cirrhosis.

  • Primary sclerosing cholangitis

     Disease statistics: 

    PSC typically begins between the ages of 30 and 50, occurring most often in men. Research has shown that it may be an autoimmune disorder, meaning that the immune system mistakes certain body parts and organs. It is estimated that 70 percent of PSC patients also suffer from ulcerative colitis. In addition, people with PSC have an increased risk of developing cholangiocarcinoma and cancer of the bile ducts.

  • Primary sclerosing cholangitis

     Disease treatment:

    Treatment for primary sclerosing cholangitis (PSC) includes medication to reduce itching and jaundice,antibiotics to treat infections and vitamin supplements since people with PSC are often deficient in vitamins A, D and K. In some cases, surgery to open major blockages in the common bile duct also is necessary. In addition, liver transplantation may be required and in some cases, can cure PSC.

Speaker PPTs

High Impact List of Articles

Conference Proceedings